PetVivo, Inc., headquartered in Ormond Beach, Florida, is a regenerative biomedical technology company specializing in veterinary applications. The company's core focus is on developing and commercializing sustained-release intra-articular therapies for animals through its proprietary RediVet injectable micro-plug system. This biodegradable polymer platform is designed to provide controlled release of therapeutic agents directly into joints, targeting osteoarthritis and related inflammatory conditions in companion and performance animals.
PetVivo’s lead product, the RediVet-40 system, has been evaluated in proof-of-concept trials involving canine patients with osteoarthritis. The platform offers potential benefits over traditional injectable treatments by extending therapeutic exposure and reducing dosing frequency. PetVivo is also exploring additional development pathways for equine and other species, leveraging its delivery technology to address unmet medical needs in veterinary orthopedics.
Founded in 2015, PetVivo has cultivated collaborations with veterinary clinics and academic research institutions across North America to advance clinical studies and support product adoption. The company maintains a portfolio of patents covering its micropellet delivery technology, underlying formulations and methods of use, underscoring its commitment to proprietary innovation in animal health and regenerative medicine.
PetVivo’s leadership team combines expertise in biomedical engineering, veterinary science and commercial product development. Through ongoing research and strategic partnerships, the company aims to expand its product pipeline and establish new channels for bringing advanced regenerative therapies to veterinary healthcare providers and their patients.
AI Generated. May Contain Errors.